Ayala Pharmaceuticals (AYLA) Stock Price, News & Analysis

Company Overview

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Key Stats

• Today's Range: $0.50 to $0.50
• 50-Day Range: $0.38 to $0.58
• 52-Week Range: $0.36 to $7.31
• Volume: N/A
• Average Volume: 76,300 shs
• Market Capitalization: $7.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AYLA Stock Analysis - Frequently Asked Questions

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) announced its quarterly earnings data on Monday, November, 15th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.80) by $0.12. The firm earned $0.63 million during the quarter, compared to analyst estimates of $0.82 million. Ayala Pharmaceuticals had a negative trailing twelve-month return on equity of 182.13% and a negative net margin of 2,341.69%.

When did Ayala Pharmaceuticals IPO?

Ayala Pharmaceuticals (AYLA) raised $50 million in an initial public offering (IPO) on Friday, May 8th 2020. The company issued 3,300,000 shares at $14.00-$16.50 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ayala Pharmaceuticals investors own include Moderna (MRNA), CrowdStrike (CRWD), Dynavax Technologies (DVAX), Block (SQ), Abbott Laboratories (ABT), Alpine Immune Sciences (ALPN) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 9/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AYLA
• CUSIP: N/A
• CIK: 1797336
• Web: www.ayalapharma.com
• Phone: 857-444-0553
• Fax: N/A
• Employees: 35
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-40,250,000.00
• Net Margins: -2,341.69%
• Pretax Margin: -2,298.60%
• Return on Equity: -182.13%
• Return on Assets: -139.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.28
• Quick Ratio: 2.28

Sales & Book Value

• Annual Sales: $3.51 million
• Price / Sales: 2.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.45 per share
• Price / Book: 0.21

Miscellaneous

• Outstanding Shares: 14,821,000
• Free Float: 14,287,000
• Market Cap: $7.46 million
• Optionable: Not Optionable
• Beta: 1.98